secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001193125-25-249438
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adverum Biotechnologies to be acquired by Eli Lilly for $3.56/sh plus CVRs worth up to $8.91/sh
--------------------------------------------------------------------------------

- Acquisition price: $3.56 per share cash plus one non-tradable CVR per share with potential payments up to $8.91 upon milestones.
- CVR milestones: $1.78/sh upon US regulatory approval for wet AMD (ADVM-022) by year 7; $7.13/sh if annual net sales exceed $1B by year 10.
- Eli Lilly provides $65M secured promissory note (SOFR+10%) with up to four advances through Dec 2025, maturing Jan 22, 2026.
- Merger via tender offer followed by Section 251(h) merger without stockholder vote; minimum tender condition of majority of shares.
- Adverum Board unanimously recommends tendering shares; termination fee of $4M payable by Adverum under certain circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525249438/0001193125-25-249438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525249438/d70157d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-249438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer